Octocrylene
Anthelios, Capital Soleil (octocrylene) is a small molecule pharmaceutical. Octocrylene was first approved as Anthelios sx on 2006-07-21.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Anthelios, Anthelios sx, Capital soleil
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avobenzone
+
Ecamsule
+
Octocrylene
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
defense total high protection spf 50 no color daily non-greasy face protection | OTC monograph final | 2023-06-20 |
la roche posay face body anthelios spf 60 melt in milk fast absorbing, velvety finish for all skin types with cell-oc shield xl | OTC monograph not final | 2022-12-29 |
vichy laboratoires capital soleil 50 daily antiaging face sunscreen broad spectrum spf 50 water resistant 80 minutes | OTC monograph not final | 2022-12-28 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | OCTOCRYLENE |
INN | octocrilene |
Description | Octocrylene is a diarylmethane. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCCC(CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1 |
Identifiers
PDB | — |
CAS-ID | 6197-30-4 |
RxCUI | 77674 |
ChEMBL ID | CHEMBL1201147 |
ChEBI ID | — |
PubChem CID | 22571 |
DrugBank | DB09535 |
UNII ID | 5A68WGF6WM (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 344 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,663 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more